A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)

NCT00405054 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
52
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Merck Sharp & Dohme LLC